Danka Radosavljevic was named Chief Operating Officer of Eton Pharmaceuticals, Inc. As of November 7, 2026, Eton Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 16, 2026 to August 4, 2026, naming 1 appointment (Form 8-K, August 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Eton Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Eton Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-16 to 2026-08-04. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Eton Pharmaceuticals, Inc. files it.
Also on the record for Eton Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by Opaleye Management Inc. | 8.54% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.9% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.01% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.7% of the class | 5%+ stakes | Source |
| December 20, 2024 | Acquired Increlex | — | Acquisition | Source |
Selling to them or working with them? See who runs Eton Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Eton Pharmaceuticals, Inc. and the records around it.
Eton Pharmaceuticals, Inc. elsewhere on the record
- Acquisition Nov 2025
- Who owns it
Companies that share a holder
- Opaleye Management Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Pasithea Therapeutics Corp. (Nov 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Eton Pharmaceuticals, Inc.
Get an email when Eton Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Eton Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Eton Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eton Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-04 | In | Chief Operating Officer | 8-K, 2026-08-04 | ||
| 2026-04-16 | Reported | not named in the filing | 8-K, 2026-04-16 |
Who leads Eton Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Danka Radosavljevic, appointed (filed 2026-08-04).
New leaders reset buying decisions — get the Full Report on Eton Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Eton Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Eton Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Danka Radosavljevic, Chief Operating Officer
On July 31, 2026, Eton Pharmaceuticals, Inc. (the "Company") appointed Danka Radosavljevic (age 42) as Chief Operating Officer.
- Ms. Radosavljevic previously held the position of Executive Vice President, Operations at the Company overseeing quality, product development, regulatory, supply chain and information systems for more than the past five years.
- Ms. Radosavljevic has been with the Company since 2017.
Reported
On April 16, 2026, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing the appointment of Judith Matthews as Executive Vice President, Accounting and Finance.
- Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026.
- Ms. Matthews will succeed James Gruber and will serve as Chief Financial Officer, Corporate Secretary and Treasurer of the Company effective June 1, 2026.
- Mr. Gruber will remain in his role with the Company through May 31, 2026 and will subsequently enter into a six-month consulting agreement with the Company.
- As an inducement to her, Ms. Matthews was granted a one-time option under the Company's equity incentive plan to purchase 37,000 shares of common stock of the Company, vesting in equal annual installments over a period of four years.
- Ms. Matthews will also be eligible to participate in the benefit plans provided to the Company's executive officers generally, as well as other benefits that are commonly found in executive employment agreements.
Tools for this story
Each opens in a new tab, filled in for Eton Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.